Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keros Therapeutics
Biotech
Keros culls phase 2 PAH program, 70 staff roles
Keros is discontinuing development of its investigational TGF-β inhibitor in PAH after the asset missed the mark in both efficacy and safety.
Gabrielle Masson
May 29, 2025 10:10am
Keros mulls sale, strengthens defense against activist investors
Apr 10, 2025 8:44am
Keros ends hypertension trial over fluid buildups around heart
Jan 15, 2025 8:25am
Keros halts 2 arms of hypertension trial over fluid near heart
Dec 12, 2024 6:30am
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Marea, Ashibio, Arvinas & more—Chutes & Ladders
Jun 21, 2024 8:30am
